Leerink Partners Maintains Bullish View on Trillium Therapeutics (TRIL) as TTI-621 Advances into Phase Ib Expansion Cohort Enrollment

November 2, 2016 11:53 AM EDT
Get Alerts TRIL Hot Sheet
Price: $6.85 -4.86%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 30 | New: 24
Trade TRIL Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and $20 price target on Trillium Therapeutics (NASDAQ: TRIL) after the company announced this morning that lead clinical program TTI-621 (SIRPa-IgG1 Fc fusion, targeting CD47) has advanced from dose escalation into the Phase Ib cohort expansion in patients with advanced hematologic malignancies.

First interim clinical data from the Phase Ia portion will be presented at the American Society of Hematology (ASH) Annual Meeting in December (with abstracts being published online on 11/03).

"We are maintaining our OP rating on TRIL as interest continues to build in targeting CD47, an emerging target in the immuno-oncology category," the analyst said.

For an analyst ratings summary and ratings history on Trillium Therapeutics click here. For more ratings news on Trillium Therapeutics click here.

Shares of Trillium Therapeutics closed at $13.60 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Add Your Comment